

SeroNet Investigators Meeting 2023

March 21-23, 2023



Abstracts

OMB No.: 0925-0740

Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Please remember to also register for the meeting. Submitting an abstract does not automatically register you for the meeting.

Late-Breaking Abstract Deadline

The deadline for late-breaking abstracts will be February 15, 2023. Abstracts detailing significant findings in the categories listed below that were not available at the time of the regular abstract deadline will be considered for presentation at the SeroNet Investigators Meeting. Those selected for an oral presentation will be notified on or around March 1, 2023. Those not selected for an oral presentation will be invited to present a poster.

Content of Abstracts

Each abstract should contain:

- An introductory sentence indicating the purposes of the study.
- A brief description of pertinent methods.
- A summary of the results.
- A statement of the conclusions.

Abstract Format (Abstract Template)

- The abstract should be a PDF file and the total length should not exceed 1 page.
- The abstract should be 500 words or less (not including title or author string) with page margins of 1".
- The abstract should be single-spaced, using Times New Roman font. All text except for the title should be normal, 12-point font.
- The abstract's title should be bold, 16-point font, and should clearly represent the nature of the investigation.
- After the title, skip one line and list the author's first and last names as well as affiliation, city, state, and country (if outside the U.S.).
- Separate multiple authors with a semicolon and underline the primary author's name (one primary author per abstract).
- Use one blank line between the title and the authors, the authors and the body of the abstract, and between paragraphs.
- The abstract file should follow this format: LastNameofPrimaryAuthor_FirstWordofTitle (e.g, Smith_SARS-CoV-2).
- Do not use subheadings (e.g., Results, Conclusions).

Note: Submissions will not be edited for spelling or grammar.

Note: Abstracts not selected for an oral presentation will be invited for a poster presentation

Abstract Submission


First Name*

Last Name*

Email*

Abstract Title*

Please indicate if you would like your abstract to be considered for an oral presentation*

- Select - 

Upload Abstract

No file chosen

PDF file only.

 [Upload requirements](#)

Submit